The Inhibitory Effect of Hydroalcoholic Extract of Black Punica Granatum Pericarp on Melanoma Tumor Angiogenesis through PPARα and PPARγ Pathways in C57BL6 Mice

Document Type : Original Article (s)

Authors

1 Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Physiology, School of Medicine AND Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Angiogenesis is the process of formation of new capillaries from the preexisting vessels and plays an important role in the growth and metastasis of tumor. In this study, we aimed to investigate the antiangiogenic effect of hydroalcoholic extract of black pomegranate pericarp extract (PPE) in the animal model of melanoma.Methods: The hydroalcoholic extract of black pomegranate pericarp was prepared using 70% ethanol containing 1% acetic acid. 1 × 106 B16F10 melanoma cells were injected to all mice on the day 0, subcutaneously (s.c). On 7th day, mice were divided into 9 groups of 8 animals. The first group received distilled water. Groups second to fifth received 50, 100, 200 and 400 mg/kg of black pomegranate pericarp extract. The sixth group received the extract and peroxisome proliferator-activated receptor gamma (PPAR-γ) antagonist (5 mg/kg/day). The seventh group received the extract and PPAR-α antagonist (10 mg/kg/day). Eighth and ninth groups received fenofibrate (100 mg/kg) and rosiglitazone (100 mg/kg) as agonists of PPAR-α and PPAR-γ, respectively. On 16th day, mice were euthanized and their tumor samples were weighed and then analyzed via immunohistochemistry staining for CD31.Findings: The black pomegranate pericarp extract dose dependently decreased tumor weight and angiogenic marker (P < 0.05). Moreover, tumor weight and angiogenic marker in the groups which received both peroxisome proliferator-activated receptor antagonists and black pomegranate pericarp extract, was more than the group which received the extract (P < 0.001). Level of angiogenesis and tumor weight in the groups which received fenofibrate and rosiglitazone was less than the group that received the highest dose of pomegranate pericarp extract (P < 0.05).Conclusion: Taken together, our observations suggest that black pomegranate pericarp extract may have potential implication in melanoma cancer treatment, and show that antiangiogenic effect of this extract may be mediated through modulation of peroxisome proliferator-activated receptor activation pathways.

Keywords

References

  1. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16(1): 5-24.
  2. Oh SH, Woo JK, Jin Q, Kang HJ, Jeong JW, Kim KW, et al. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 2008; 122(1): 5-14.
  3. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
  4. Yasui Y, Kim M, Tanaka T. PPAR ligands for cancer chemoprevention. PPAR Res 2008; 2008: 548919.
  5. Freudlsperger C, Schumacher U, Reinert S, Hoffmann J. The critical role of PPARgamma in human malignant melanoma. PPAR Res 2008; 2008: 503797.
  6. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3(7): 643-51.
  7. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. Leukemia 2007; 21(1): 44-52.
  8. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007; 34(6): 555-65.
  9. Ribatti D, Nico B, Floris C, Mangieri D, Piras F, Ennas MG, et al. Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncol Rep 2005; 14(1): 81-4.
  10. Leong A, Cooper K, Leong JWM. Manual of diagnostic antibodies for immunohistology. Cambridge, UK: Cambridge University Press; 2003.
  11. Sagar SM, Yance D, Wong RK. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. Curr Oncol 2006; 13(3): 99-107.
  12. Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD. Approaches to preclinical screening of antiangiogenic agents. Semin Oncol 2001; 28(6): 570-6.
  13. Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 2007; 109(2): 177-206.
  14. Viladomiu M, Hontecillas R, Lu P, Bassaganya-Riera J. Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med 2013; 2013: 789764.
  15. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 2008; 13(2): 128-44.
  16. Fotsis T, Pepper MS, Montesano R, Aktas E, Breit S, Schweigerer L, et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 1998; 12(4): 649-66.
  17. Le ML. Cancer preventive effects of flavonoids--a review. Biomed Pharmacother 2002; 56(6): 296-301.
  18. Ni Q, Xu G, Lu G, Gao Q, Zhou C, Zhang Y. Investigation of the stability and antioxidant properties of anthocyanins-based purple potato colorants after processing. African Journal of Biotechnology 2012; 11(14): 3379-87.
  19. Oancea S, Draghici O. pH and thermal stability of anthocyanin-based optimised extracts of Romanian red onion cultivars. Czech Journal of Food Science 2013; 31(3): 283-91.
  20. Downer EJ, Clifford E, Amu S, Fallon PG, Moynagh PN. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-beta expression via peroxisome proliferator-activated receptor-alpha. J Biol Chem 2012; 287(30): 25440-53.
  21. Nakajima A, Tomimoto A, Fujita K, Sugiyama M, Takahashi H, Ikeda I, et al. Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Sci 2008; 99(10): 1892-900.
  22. Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 2003; 6(2): 121-8.
  23. Dana N, Haghjooy Javanmard S, Fazilati M. Anti-angiogenic effects of pomegranate peel extract (Punica Granatum L.) on human umbilical vein endothelial cells. J Isfahan Med Sch 2012; 30(195): 913-21. [In Persian].
  24. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 2008; 32(2): 475-80.
  25. Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A, et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004; 7(3): 274-83.
  26. Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71(3): 203-17.
  27. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105(3): 985-90.
  28. Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer. PPAR Res 2008; 2008: 431763.
  29. Christaki EV, Bonos EM, Florou-Paneri PC. Dietary benefits of pomegranates in humans and animals. Food, Agriculture and Environment 2011; 9(1): 142-4.
  30. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 2004; 10(6): 2190-202.
  31. Sartippour MR, Heber D, Zhang L, Beatty P, Elashoff D, Elashoff R, et al. Inhibition of fibroblast growth factors by green tea. Int J Oncol 2002; 21(3): 487-91.
  32. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005; 16(6): 360-7.
Journal of Isfahan Medical School
Volume 33, Issue 331 - Serial Number 331
March and April 2015
Pages 536-545

Files

History

  • Receive Date: 22 January 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics